Piecing Together the Adrenal Puzzle: CAI Score and Postoperative Testing

Unfolding the Adrenal Puzzle: Methodologies, Signals, and Clinical Context from Recent Endocrine Society–Generated Work

The shared emphasis across these pieces is on enhancing diagnostic accuracy, refining postoperative management, and understanding rare or intricate adrenal pathologies to ultimately support patient outcomes.

The content provided does not extend beyond what is reported in the source; no extrapolations, recommendations, or numerical claims beyond what is explicitly stated are added.

• This synthesis distills a quartet of studies highlighted in Endocrine News, with publication footprints anchored in Endocrine Society journals.

The researchers sought to improve decision-making for suspected CAI patients with indeterminate morning cortisol levels by creating a predictive scoring system that surpasses the diagnostic performance of morning cortisol alone.

The reference standard used was the short Synacthen test (SST).

The context acknowledges the clinical challenge posed by gray-zone cortisol readings, defined in the study with a deliberate expansion of practical boundaries.

The CAI score is presented as a web-based predictive tool intended for real-world application and potential integration into clinical workflows.

The study also emphasizes the noninvasiveness and practical accessibility of the tool, noting that it is free and currently sharable via a public web interface.

The authors frame this as evidence that disease impact on surrounding pituitary tissue—reflected in additional hormonal losses—drives CAI risk more robustly than purely radiographic tumor burden.

They stress that AI-enhanced tools are meant to augment, not replace, clinical judgment.

institutions examining postoperative adrenal function after unilateral adrenalectomy performed for mild autonomous cortisol secretion (MACS).

The study tested two cortisol assessment modalities—basal cortisol and cosyntropin stimulation testing (CST)—to determine how often adrenal insufficiency occurs, whether basal cortisol suffices for assessment, and whether biochemical or clinical severity aligns with the duration of postoperative HPA axis suppression and recovery.

centers.

The study sought to compare the value and discordance between these two testing strategies and to examine recovery trajectories and predictors of recovery duration.

Two salient observations emerged: (a) discordance between basal cortisol and CST occurred in roughly 22% of patients, suggesting that reliance on a single test could misclassify a meaningful subset; (b) younger age emerged as a strong predictor of prolonged biochemical suppression and recovery duration, with more severe biosignatures associated with extended persistence of insufficiency.

Specifically, those with milder impairment recovered on a shorter timescale (around three months) while more severe suppression extended recovery to four to 14 months.

They propose using objective biochemical data to tailor glucocorticoid replacement decisions and to inform patient-specific recovery trajectories and expectations.

They consider standardized, multicenter testing protocols and ongoing prospective validation to be important future steps.

Standard imaging and biochemical pathways did not support a pheochromocytoma diagnosis, prompting surgical excision.

Pathology identified a pure adrenal ganglioneuroma with ACTH immunostaining, explaining ACTH-driven cortisol excess.

The report emphasizes that AGNs are typically benign and nonsecretory but can display secretory activity; this case illustrates how secretory AGN should feature in the differential diagnosis for ACTH-dependent hypercortisolism with an adrenal lesion, particularly when imaging and laboratory cues diverge from more common etiologies.

The case underscores the necessity of histopathologic confirmation to resolve diagnostic ambiguity.

The patient’s history included a pituitary macroprolactinoma treated surgically, and genetic testing confirmed a MEN1 mutation.

Following surgical intervention (adrenalectomy and distal pancreatectomy), the patient died from postoperative sepsis and septic shock, with Cushing syndrome likely increasing infectious risk.

The narrative emphasizes that comprehensive genetic evaluation and family surveillance can influence downstream surveillance strategies and timely intervention.

They also illustrate how MEN1-driven adrenal pathology may present with multifocal endocrine disease and carry significant prognostic and familial implications.

• Central adrenal insufficiency (CAI) diagnostic optimization:
• Study aim and design: A retrospective, single-center evaluation conducted at a Riyadh tertiary referral center.
• Population and setting: 341 adults with suspected CAI and indeterminate morning cortisol values.
• Intervention: Integration of morning cortisol with a set of clinical and radiologic features, including pituitary hormone deficits, tumor size, sex, and treatment history, underpinned by a machine learning approach to generate a CAI score.
• Outcome focus in source: The CAI score demonstrated superior diagnostic accuracy relative to morning cortisol alone, offering a risk-stratified approach to determine whether dynamic testing is warranted.
• Interpretive notes: The authors highlight two unexpected findings: (1) the presence of three or more additional pituitary hormone deficits as a striking predictor of CAI (odds ratio in excess of 35, underscoring that CAI frequently signals broader pituitary dysfunction), and (2) a relatively modest role for tumor size in predicting CAI compared with the extent of pituitary dysfunction.
• Implications and next steps acknowledged: The authors anticipate external validation across diverse clinical environments and the demonstration of practical value in reducing unnecessary testing and costs, while preserving patient safety.
• Postoperative assessment for adrenal insufficiency after adrenalectomy for MACS:
• Study aim and design: A multicenter retrospective study across five U.S.
• Population and setting: 281 MACS patients (about 80% female; median age 57) who underwent unilateral adrenalectomy, with data drawn from five U.S.
• Interventions and comparator: Diagnostic testing postoperatively employed basal cortisol measurements and CST to detect adrenal insufficiency.
• Outcome focus in source: Approximately half of the cohort developed postoperative adrenal insufficiency.
• Practical implications and future directions: The authors advocate for earlier postoperative testing—beginning around four to six weeks after surgery and continuing at planned intervals—to improve management and avoid both under-treatment and unnecessarily prolonged glucocorticoid exposure.
• Limitations acknowledged: The authors note uncertainty about the optimal timing and emphasize that a preoperative risk score would face intrinsic limitations, especially given that the duration of cortisol autonomy is often uncertain or undetectable before the operation.
• Rare presentations and instructive lessons: two case reports from JCEM Case Reports (March 2025):
• ACTH-secreting pure adrenal ganglioneuroma causing Cushing syndrome:
• Clinical vignette and diagnostic journey: A 23-year-old man presented with hypertension, an adrenal mass, anxiety, and diaphoresis; laboratory testing revealed ACTH-dependent hypercortisolism with elevated 24-hour urinary free cortisol and lack of suppression on low-dose dexamethasone testing.
• Postoperative course and interpretation: Blood pressure normalization without antihypertensives and normalization of urinary free cortisol followed surgically.
• MEN1-associated adrenal cortical carcinoma: a long-term surveillance case
• Clinical vignette: A 49-year-old woman presented with recurrent hypoglycemia and was found to have a constellation of endocrine abnormalities including insulinoma, primary hyperparathyroidism, and a large left adrenal mass producing ACTH-independent hypercortisolism.
• Pathology and outcome: The adrenal lesion was diagnosed as a mucinous adrenocortical carcinoma, a high-grade and rare entity.
• Family implications and emphasis: Genetic testing of relatives revealed the patient’s 11-year-old son carried the MEN1 mutation, highlighting the importance of family screening for early detection and potential outcome improvement.
• The common thread from the case reports: collectively, these narratives reinforce the diagnostic complexity of adrenal lesions, the potential for secretory activity in lesions typically considered nonsecretory, and the central role of definitive histopathologic evaluation in resolving etiologic uncertainty.

The portrayal acknowledges that while the population-level figures appear modest, they translate into substantial clinical journeys characterized by diagnostic ambiguity, management challenges, and patient-centered impacts on daily life.

• The Endocrine Facts and Figures citation anchors the profile of adrenal disorders in epidemiologic terms, providing prevalence estimates for primary adrenal insufficiency, Cushing syndrome, Cushing disease, and MEN1.
• Across the included studies, several themes recur: the limitations of isolated cortisol measures in isolation, the potential for ambiguity in adrenal axis assessment postoperatively, and the necessity of integrating diverse data points (labs, imaging, clinical phenotype, genetic context) to inform risk and management decisions.

The CAI score's architecture integrates biochemical, structural, and historical data to triangulate CAI risk; its ongoing value hinges on external validation and demonstrated workflow practicality.

The work highlights a broader editorial point in endocrinology: complex pituitary axis disorders are rarely the product of a lone measurement; rather, they reflect interconnected endocrine networks that may be only partially captured by individual tests.

The explicit recognition of pituitary deficits as a major predictor adds a nuance: cumulative endocrine compromise can be a stronger diagnostic beacon than tumor size alone.

The discordance between basal cortisol and CST in a sizable minority suggests that single-test strategies risk misclassification.

The age-related finding conveys a provocative observation that younger patients might experience deeper or more prolonged suppression, challenging assumptions based on older paradigms and inviting prospective validation to understand the mechanism.

An ACTH-secreting adrenal ganglioneuroma exemplifies how rare tumor biology can mimic other etiologies, reinforcing the imperative for histologic assessment to secure a definitive diagnosis.

The MEN1-associated adrenal carcinoma case demonstrates how a syndromic genetic background can yield aggressive tumor biology, with implications for familial screening, surveillance planning, and risk stratification in asymptomatic mutation carriers.

These narratives collectively emphasize a cautious clinical posture: even rare or atypical adrenal lesions demand thorough evaluation, including consideration of noncanonical etiologies and genetic context.

• Diagnostic refinement in CAI underscores the potential for machine-assisted, multi-parameter tools to sharpen risk stratification beyond single biomarker reliance.
• Postoperative adrenal insufficiency after MACS surgery raises a practical tension in endocrine practice: balancing avoidance of unnecessary glucocorticoid exposure with the risk of undertreatment in patients who fail to recover adrenal function promptly.
• The case reports illuminate the breadth of adrenal pathology beyond routine expectations.

The approach hinges on credible integration into electronic health records and clinician acceptance of AI-assisted risk estimates as decision-support rather than as decision-makers.

Acknowledgement of test discordance supports a multimodal assessment approach rather than reliance on a single cortisol metric.

They also highlight genetic testing's relevance for MEN1 and family screening as a strategic element of care.

The MEN1 case foregrounds genetic counseling and family-based risk management as integral to care.

• Diagnostic workflows and resource implications:
• CAI: The CAI scoring tool promises a more integrated decision pathway that could reduce unnecessary dynamic testing if externally validated.
• Postoperative MACS: The evidence supports structured postoperative surveillance with earlier testing windows (4–6 weeks) and repeated assessments to tailor glucocorticoid exposure and withdrawal based on measured recovery trajectories.
• Rare pathologies: The case studies reaffirm the necessity of histopathological confirmation for unusual adrenal lesions and the requirement to consider ACTH-dependent processes in the differential diagnosis when compatible clinical cues exist.
• Patient safety and quality of care considerations:
• For CAI, the intended utility of the CAI score is to improve diagnostic accuracy and to help avoid unnecessary dynamic testing, with the ultimate aim of improving patient safety and resource utilization.
• After MACS adrenalectomy, a cautious approach to glucocorticoid stewardship is recommended, driven by structured re-evaluation rather than empirical continuation or cessation—an approach designed to reduce adverse effects while preserving hormonal balance.
• In rare tumors, precise histology and immunohistochemistry are central to diagnosis, guiding prognostication and long-term surveillance.

The degree to which the tool will affect real-world testing patterns and healthcare costs remains to be demonstrated.

The authors acknowledge that the findings require prospective confirmation and standardized protocols across centers to become generalizable.

The authors propose mechanistic hypotheses and future longitudinal modeling to clarify the age-related trajectories of HPA axis recovery.

They underscore the necessity for comprehensive histopathology and genetic assessment when encountering atypical adrenal presentations, but they do not provide generalized management guidelines beyond the explicit narratives.

• External validation gaps for CAI: While the CAI score showed improved diagnostic performance in the single-center experience, the authors explicitly call for validation across broader patient populations and practice settings to ensure reproducibility and practical value.
• Postoperative testing timing and generalizability: The MACS study articulates uncertainty about the optimal postoperative timing for testing and the interpretation of discordant basal cortisol versus CST results.
• Mechanistic understanding of age effects: The observation that younger patients demonstrated deeper or more prolonged recovery needs further exploration, as the study anticipates.
• Rare pathology implications for management: The two case reports illuminate diagnostic complexity rather than broad treatment recommendations.